Active Pharmaceutical Ingredients (API) Market Size And Forecast By Type of Synthesis (Biotech, Synthetic), By Type of Manufacturer (Captive, Merchant), By Type (Generic, Innovative), By Application And Trend Analysis, 2014 - 2025
出 版 商：Grand View Research
出版日期：2017/01/02
頁 數：95頁
文件格式：PDF
價 格：
USD 4,950 (Single-User License)
USD 7,950 (Multi-User License)
USD 9,950 (Global-User License)
USD 7,950 (Multi-User License)
USD 9,950 (Global-User License)
The global active pharmaceutical pngredients (API) market is expected to reach a value of USD 239.8 billion by 2025, based on a new report by Grand View Research, Inc. The rising prevalence of lifestyle-induced & age-related diseases and cancer is projected to drive the market over the forecast period. Advancements in recombinant molecular technologies and high capitalization for development of novel drugs are also estimated to boost growth.
Favorable government initiatives for increasing focus toward generic drugs is a key factor for market growth. Decrease in generic drug prices, higher acceptance in low income and decrease in reimbursement for branded drugs are the recent trends in the market affirming growth of generic drugs.
Further Key Findings from the Study Suggest:
Synthetic APIs was the largest segment by revenue share in 2015 owing to high demand.
Biotech APIs are estimated to grow lucratively over the forecast period with high R&D initiatives being undertaken for their development
Captive manufacturers, being the conventional option of API manufacturing, held the majority of the share.
On the other hand, the merchant manufacturers segment is expected to be fastest-growing due to growing outsourcing activities
Generic APIs will experience lucrative growth over the forecast period attributed to patent expirations of branded drugs
APIs are identified to have highest application in cardiovascular therapeutics. Increasing mortality caused by heart diseases and growing demand for fast-acting drugs are the major factors contributing to dominance
North America dominated in terms of revenue share in 2015 and Asia Pacific is expected to grow at a significant growth rate over the forecast period
Some of the major companies in the API market are AbbVie, Inc., Boehringer Ingelheim GmbH, Cipla, Inc., and Merck & Co., Inc.
Favorable government initiatives for increasing focus toward generic drugs is a key factor for market growth. Decrease in generic drug prices, higher acceptance in low income and decrease in reimbursement for branded drugs are the recent trends in the market affirming growth of generic drugs.
Further Key Findings from the Study Suggest:
Synthetic APIs was the largest segment by revenue share in 2015 owing to high demand.
Biotech APIs are estimated to grow lucratively over the forecast period with high R&D initiatives being undertaken for their development
Captive manufacturers, being the conventional option of API manufacturing, held the majority of the share.
On the other hand, the merchant manufacturers segment is expected to be fastest-growing due to growing outsourcing activities
Generic APIs will experience lucrative growth over the forecast period attributed to patent expirations of branded drugs
APIs are identified to have highest application in cardiovascular therapeutics. Increasing mortality caused by heart diseases and growing demand for fast-acting drugs are the major factors contributing to dominance
North America dominated in terms of revenue share in 2015 and Asia Pacific is expected to grow at a significant growth rate over the forecast period
Some of the major companies in the API market are AbbVie, Inc., Boehringer Ingelheim GmbH, Cipla, Inc., and Merck & Co., Inc.
Table of Contents
Chapter 1 Research Methodology & Scope
1.1 Information Procurement
1.1.1 Purchased database:
1.1.2 GVR’s internal database
1.2 Research Methodology
1.3 Geographic scope & assumptions
1.4 Region-wise market calculation
1.4.1 Region-wise market: Base estimates
1.4.2 Global market: CAGR calculation
1.5 Region-based segment share calculation
1.6 List of Secondary Sources
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 API Market Variables, Trends & Scope
3.1 Market segmentation & scope
3.1.1 Market Driver Analysis
3.1.1.1 Growing geriatric population base
3.1.1.2 Growing prevalence of target diseases such as hospital acquired infections, genetic, cardiovascular and neurological diseases
3.1.1.3 Increasing preference for targeted therapy approach in cancer treatment
3.1.1.4 Increasing preference for outsourcing APIs
3.1.2 Market restraint analysis
3.1.2.1 Large capital investments and production cost
3.1.3 Stringent safety and handling regulations regarding APIs
3.2 Penetration & growth prospect mapping
3.3 Active Pharmaceutical Ingredient - SWOT Analysis, By Factor (political & legal, economic and technological)
3.4 Industry Analysis - Porter’s
Chapter 4 API Market: Type of Synthesis Estimates & Trend Analysis
4.1 Active pharmaceutical ingredient market: Type of synthesis movement analysis
4.2 Biotech
4.2.1 Biotech market, 2014 - 2025 (USD Billion)
4.2.2 Monoclonal Antibodies
4.2.3 Monoclonal Antibodies market, 2014 - 2025 (USD Billion)
4.2.4 Recombinant proteins
4.2.5 Recombinant proteins market, 2014 - 2025 (USD Billion)
4.2.6 Vaccines
4.2.7 Vaccines market, 2014 - 2025 (USD Billion)
4.3 Synthetic
4.3.1 Synthetic market, 2014 - 2025 (USD Billion)
Chapter 5 API Market: Type of Manufacturer Estimates & Trend Analysis
5.1 Active pharmaceutical ingredient market: Type of Manufacturer movement analysis
5.2 Captive APIs
5.2.1 Captive APIs market, 2014 - 2025 (USD Billion)
5.3 Merchant APIs
5.3.1 Merchant APIs market, 2014 - 2025 (USD Billion)
Chapter 6 API Market: Type Estimates & Trend Analysis
6.1 Active pharmaceutical ingredient market: Type movement analysis
6.2 Generic APIs
6.2.1 Generic APIs market, 2014 - 2025 (USD Billion)
6.3 Innovative APIs
6.3.1 Innovative APIs market, 2014 - 2025 (USD Billion)
Chapter 7 API Market: Application Estimates & Trend Analysis
7.1 Active pharmaceutical ingredient market: Application movement analysis
7.2 Cardiovascular Disease
7.2.1 Cardiovascular Disease market, 2014 - 2025 (USD Billion)
7.3 Oncology
7.3.1 Oncology market, 2014 - 2025 (USD Billion)
7.4 CNS and Neurological Disorders
7.4.1 CNS and Neurological Disorders market, 2014 - 2025 (USD Billion)
7.5 Orthopedic Disorders
7.5.1 Orthopedic Disorders market, 2014 - 2025 (USD Billion)
7.6 Endocrinology
7.6.1 Endocrinology market, 2014 - 2025 (USD Billion)
7.7 Pulmonology
7.7.1 Pulmonology market, 2014 - 2025 (USD Billion)
7.8 Gastrointestinal Disorders
7.8.1 Gastrointestinal Disorders market, 2014 - 2025 (USD Billion)
7.9 Nephrology
7.9.1 Nephrology market, 2014 - 2025 (USD Billion)
7.10 Ophthalmology
7.10.1 Ophthalmology market, 2014 - 2025 (USD Billion)
7.10.2 Others market, 2014 - 2025 (USD Billion)
Chapter 8 API Market: Regional Estimates & Trend Analysis
8.1 Active pharmaceutical ingredient market share, by region, 2015 & 2025
8.2 North America
8.2.1 North America active pharmaceutical ingredient market, 2014 - 2025 (USD Billion)
8.2.2 U.S
8.2.2.1 U.S active pharmaceutical Ingredient market, 2014 - 2025 (USD Billion)
8.2.3 Canada
8.2.3.1 Canada active pharmaceutical ingredient market, 2014 - 2025 (USD Billion)
8.3 Europe
8.3.1 Europe active pharmaceutical ingredient market, 2014 - 2025 (USD Billion)
8.3.2 UK
8.3.2.1 UK active pharmaceutical ingredient market, 2014 - 2025 (USD Billion)
8.3.3 Germany
8.3.3.1 Germany active pharmaceutical ingredient market, 2014 - 2025 (USD Billion)
8.4 Asia Pacific
8.4.1 Asia Pacific active pharmaceutical ingredient market, 2014 - 2025 (USD Billion)
8.4.2 Japan
8.4.2.1 Japan active pharmaceutical ingredient market, 2014 - 2025 (USD Billion)
8.4.3 China
8.4.3.1 China active pharmaceutical ingredient market, 2014 - 2025 (USD Billion)
8.4.4 India
8.4.4.1 India active pharmaceutical ingredient market, 2014 - 2025 (USD Billion)
8.5 Latin America
8.5.1 Latin America active pharmaceutical ingredient market, 2014 - 2025 (USD Billion)
8.5.2 Brazil
8.5.2.1 Brazil active pharmaceutical ingredient market, 2014 - 2025 (USD Billion)
8.5.3 Mexico
8.5.3.1 Mexico active pharmaceutical ingredient market, 2014 - 2025 (USD Billion)
8.6 MEA
8.6.1 MEA active pharmaceutical ingredient market, 2014 - 2025 (USD Billion)
8.6.2 South Africa
8.6.2.1 South Africa active pharmaceutical ingredient market, 2014 - 2025 (USD Billion)
Chapter 9 Competitive Landscape
9.1 Strategy Framework
9.2 Market Participation Categorization
9.3 Company Profiles
9.3.1 AbbVie, Inc.
9.3.1.1 Company overview
9.3.1.2 Financial performance
9.3.1.3 Product benchmarking
9.3.1.4 Strategic initiatives
9.3.2 Boehringer Ingelheim GmbH
9.3.2.1 Company overview
9.3.2.2 Financial performance
9.3.2.3 Product benchmarking
9.3.2.4 Strategic initiatives
9.3.3 Bristol-Myers Squibb Company
9.3.3.1 Company overview
9.3.3.2 Financial performance
9.3.3.3 Product benchmarking
9.3.3.4 Strategic initiatives
9.3.4 Cipla, Inc.
9.3.4.1 Company overview
9.3.4.2 Financial performance
9.3.4.3 Product benchmarking
9.3.4.4 Strategic initiatives
9.3.5 Merck& Co., Inc.
9.3.5.1 Company overview
9.3.5.2 Financial performance
9.3.5.3 Product benchmarking
9.3.5.4 Strategic initiatives
9.3.6 Albemarle Corporation
9.3.6.1 Company overview
9.3.6.2 Financial overview
9.3.6.3 Product benchmarking
9.3.6.4 Strategic initiatives
9.3.7 Aurobindo Pharma
9.3.7.1 Company overview
9.3.7.2 Financial overview
9.3.7.3 Product benchmarking
9.3.7.4 Strategic initiatives
9.3.8 Mylan N.V.
9.3.8.1 Company overview
9.3.8.2 Financial overview
9.3.8.3 Product benchmarking
9.3.8.4 Strategic initiatives
9.3.9 Teva Active Pharmaceuticals Industries Ltd.
9.3.9.1 Company overview
9.3.9.2 Financial overview
9.3.9.3 Product benchmarking
9.3.9.4 Strategic initiatives
9.3.10 Sun Pharmaceutical Industries, Ltd.
9.3.10.1 Company overview
9.3.10.2 Financial overview
9.3.10.3 Product benchmarking
9.3.10.4 Strategic initiatives
9.3.11 Dr. Reddy’s Laboratories Ltd
9.3.11.1 Company overview
9.3.11.2 Financial overview
9.3.11.3 Product benchmarking
9.3.11.4 Strategic initiatives
Chapter 1 Research Methodology & Scope
1.1 Information Procurement
1.1.1 Purchased database:
1.1.2 GVR’s internal database
1.2 Research Methodology
1.3 Geographic scope & assumptions
1.4 Region-wise market calculation
1.4.1 Region-wise market: Base estimates
1.4.2 Global market: CAGR calculation
1.5 Region-based segment share calculation
1.6 List of Secondary Sources
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 API Market Variables, Trends & Scope
3.1 Market segmentation & scope
3.1.1 Market Driver Analysis
3.1.1.1 Growing geriatric population base
3.1.1.2 Growing prevalence of target diseases such as hospital acquired infections, genetic, cardiovascular and neurological diseases
3.1.1.3 Increasing preference for targeted therapy approach in cancer treatment
3.1.1.4 Increasing preference for outsourcing APIs
3.1.2 Market restraint analysis
3.1.2.1 Large capital investments and production cost
3.1.3 Stringent safety and handling regulations regarding APIs
3.2 Penetration & growth prospect mapping
3.3 Active Pharmaceutical Ingredient - SWOT Analysis, By Factor (political & legal, economic and technological)
3.4 Industry Analysis - Porter’s
Chapter 4 API Market: Type of Synthesis Estimates & Trend Analysis
4.1 Active pharmaceutical ingredient market: Type of synthesis movement analysis
4.2 Biotech
4.2.1 Biotech market, 2014 - 2025 (USD Billion)
4.2.2 Monoclonal Antibodies
4.2.3 Monoclonal Antibodies market, 2014 - 2025 (USD Billion)
4.2.4 Recombinant proteins
4.2.5 Recombinant proteins market, 2014 - 2025 (USD Billion)
4.2.6 Vaccines
4.2.7 Vaccines market, 2014 - 2025 (USD Billion)
4.3 Synthetic
4.3.1 Synthetic market, 2014 - 2025 (USD Billion)
Chapter 5 API Market: Type of Manufacturer Estimates & Trend Analysis
5.1 Active pharmaceutical ingredient market: Type of Manufacturer movement analysis
5.2 Captive APIs
5.2.1 Captive APIs market, 2014 - 2025 (USD Billion)
5.3 Merchant APIs
5.3.1 Merchant APIs market, 2014 - 2025 (USD Billion)
Chapter 6 API Market: Type Estimates & Trend Analysis
6.1 Active pharmaceutical ingredient market: Type movement analysis
6.2 Generic APIs
6.2.1 Generic APIs market, 2014 - 2025 (USD Billion)
6.3 Innovative APIs
6.3.1 Innovative APIs market, 2014 - 2025 (USD Billion)
Chapter 7 API Market: Application Estimates & Trend Analysis
7.1 Active pharmaceutical ingredient market: Application movement analysis
7.2 Cardiovascular Disease
7.2.1 Cardiovascular Disease market, 2014 - 2025 (USD Billion)
7.3 Oncology
7.3.1 Oncology market, 2014 - 2025 (USD Billion)
7.4 CNS and Neurological Disorders
7.4.1 CNS and Neurological Disorders market, 2014 - 2025 (USD Billion)
7.5 Orthopedic Disorders
7.5.1 Orthopedic Disorders market, 2014 - 2025 (USD Billion)
7.6 Endocrinology
7.6.1 Endocrinology market, 2014 - 2025 (USD Billion)
7.7 Pulmonology
7.7.1 Pulmonology market, 2014 - 2025 (USD Billion)
7.8 Gastrointestinal Disorders
7.8.1 Gastrointestinal Disorders market, 2014 - 2025 (USD Billion)
7.9 Nephrology
7.9.1 Nephrology market, 2014 - 2025 (USD Billion)
7.10 Ophthalmology
7.10.1 Ophthalmology market, 2014 - 2025 (USD Billion)
7.10.2 Others market, 2014 - 2025 (USD Billion)
Chapter 8 API Market: Regional Estimates & Trend Analysis
8.1 Active pharmaceutical ingredient market share, by region, 2015 & 2025
8.2 North America
8.2.1 North America active pharmaceutical ingredient market, 2014 - 2025 (USD Billion)
8.2.2 U.S
8.2.2.1 U.S active pharmaceutical Ingredient market, 2014 - 2025 (USD Billion)
8.2.3 Canada
8.2.3.1 Canada active pharmaceutical ingredient market, 2014 - 2025 (USD Billion)
8.3 Europe
8.3.1 Europe active pharmaceutical ingredient market, 2014 - 2025 (USD Billion)
8.3.2 UK
8.3.2.1 UK active pharmaceutical ingredient market, 2014 - 2025 (USD Billion)
8.3.3 Germany
8.3.3.1 Germany active pharmaceutical ingredient market, 2014 - 2025 (USD Billion)
8.4 Asia Pacific
8.4.1 Asia Pacific active pharmaceutical ingredient market, 2014 - 2025 (USD Billion)
8.4.2 Japan
8.4.2.1 Japan active pharmaceutical ingredient market, 2014 - 2025 (USD Billion)
8.4.3 China
8.4.3.1 China active pharmaceutical ingredient market, 2014 - 2025 (USD Billion)
8.4.4 India
8.4.4.1 India active pharmaceutical ingredient market, 2014 - 2025 (USD Billion)
8.5 Latin America
8.5.1 Latin America active pharmaceutical ingredient market, 2014 - 2025 (USD Billion)
8.5.2 Brazil
8.5.2.1 Brazil active pharmaceutical ingredient market, 2014 - 2025 (USD Billion)
8.5.3 Mexico
8.5.3.1 Mexico active pharmaceutical ingredient market, 2014 - 2025 (USD Billion)
8.6 MEA
8.6.1 MEA active pharmaceutical ingredient market, 2014 - 2025 (USD Billion)
8.6.2 South Africa
8.6.2.1 South Africa active pharmaceutical ingredient market, 2014 - 2025 (USD Billion)
Chapter 9 Competitive Landscape
9.1 Strategy Framework
9.2 Market Participation Categorization
9.3 Company Profiles
9.3.1 AbbVie, Inc.
9.3.1.1 Company overview
9.3.1.2 Financial performance
9.3.1.3 Product benchmarking
9.3.1.4 Strategic initiatives
9.3.2 Boehringer Ingelheim GmbH
9.3.2.1 Company overview
9.3.2.2 Financial performance
9.3.2.3 Product benchmarking
9.3.2.4 Strategic initiatives
9.3.3 Bristol-Myers Squibb Company
9.3.3.1 Company overview
9.3.3.2 Financial performance
9.3.3.3 Product benchmarking
9.3.3.4 Strategic initiatives
9.3.4 Cipla, Inc.
9.3.4.1 Company overview
9.3.4.2 Financial performance
9.3.4.3 Product benchmarking
9.3.4.4 Strategic initiatives
9.3.5 Merck& Co., Inc.
9.3.5.1 Company overview
9.3.5.2 Financial performance
9.3.5.3 Product benchmarking
9.3.5.4 Strategic initiatives
9.3.6 Albemarle Corporation
9.3.6.1 Company overview
9.3.6.2 Financial overview
9.3.6.3 Product benchmarking
9.3.6.4 Strategic initiatives
9.3.7 Aurobindo Pharma
9.3.7.1 Company overview
9.3.7.2 Financial overview
9.3.7.3 Product benchmarking
9.3.7.4 Strategic initiatives
9.3.8 Mylan N.V.
9.3.8.1 Company overview
9.3.8.2 Financial overview
9.3.8.3 Product benchmarking
9.3.8.4 Strategic initiatives
9.3.9 Teva Active Pharmaceuticals Industries Ltd.
9.3.9.1 Company overview
9.3.9.2 Financial overview
9.3.9.3 Product benchmarking
9.3.9.4 Strategic initiatives
9.3.10 Sun Pharmaceutical Industries, Ltd.
9.3.10.1 Company overview
9.3.10.2 Financial overview
9.3.10.3 Product benchmarking
9.3.10.4 Strategic initiatives
9.3.11 Dr. Reddy’s Laboratories Ltd
9.3.11.1 Company overview
9.3.11.2 Financial overview
9.3.11.3 Product benchmarking
9.3.11.4 Strategic initiatives
